Body sites value set for AIR immunisations

Coded values to describe the reason an immunisation was given. Initially drawn from legacy NIR codes and CIR SNOMED codes.

A value set of codes for the functions performed by vaccinators.

Australian and New Zealand Standard Classification of Occupations (ANZSCO)

Absent or Unknown Allergies

Absent or Unknown Devices

Absent or Unknown Immunization

Absent or Unknown Medication

Absent or Unknown Problems

Absent or Unknown Procedures

The gender of a person used for administrative purposes.

Codes used for admission source that are required to be reporting into National Collections

Admission type code for reporting into National Collections

The severity of the adverse event itself, in direct relation to the subject.

Agency type code to be used to reporting to National Collections

The complete set of alias types that apply to Locations and Organizations

IPS Allergy intolerance codes value set. This value set includes codes from SNOMED Clinical Terms®: all descendants of 373873005 |Pharmaceutical / biologic product (product)|; all descendants of 105590001 |Substance (substance)|; all descendants of 418038007 |Propensity to adverse reactions to substance (finding)| plus codes for absent and unknown allergies.

IPS Allergy intolerance substance condition value set. This value set includes codes from SNOMED Clinical Terms®: all descendants of 373873005 |Pharmaceutical / biologic product (product)|; all descendants of 105590001 |Substance (substance)|; all descendants of 418038007 |Propensity to adverse reactions to substance (finding)|

IPS allergy reaction value set. This value set includes the codes from the SNOMED International Patient Set (IPS) subset of SNOMED CT (IPS Free Set) that may be used to represent allergy or intolerance reactions.

Category of an identified substance associated with allergies or intolerances.

Estimate of the potential clinical harm, or seriousness, of a reaction to an identified substance.

Clinical assessment of the severity of a reaction event as a whole, potentially considering multiple different manifestations.

Identification of the underlying physiological mechanism for a Reaction Risk.

IPS body site value set. This value set includes a set of codes from SNOMED CT that may be used to represent body sites (e.g., for laboratory specimen collection).

Clinical code type to be used in reporting to National Collections

Clinical coding system code to be used in reporting to national Collections

Commonly encountered UCUM units (for purposes of helping populate look ups.

Preferred value set for Condition Clinical Status.

Preferred value set for Condition/Diagnosis severity grading.

The verification status to support or decline the clinical status of the condition or diagnosis.

The purpose of a ContactPoint - what it is used for.

New Zealand codes for Coverage Types

HL7 LOINC value set for smoking status. Based on the HL7 Vocab and Structured Doc WG (formerly TC) consensus - per US CDC submission 7/12/2012 for smoking status terms.

DSM-IV

Datum codes used

The source from where the date of death was sourced

District Health Board Identifer. Assigned by the HPI.

Whether the application produces or consumes documents.

Domicile Code

Codes to record a person’s ethnicity, drawn from Level 4 of the Ethnicity code system Note that the correct version of the ethicity code system is 2.1.0

NZ ethnic group codes that cover every ethnicity level

Some sort of funded programme

ISO 639-2 language codes plus NZ sign language from ISO 639-3

IPS Healthcare Professional Roles

ISO 3166-1 alpha-2 country codes

iso 639-2 and 639-3 language codes

ISO 639-3 language codes

The source from where the value of this item was sourced

New Zealand iwi codes

This value set includes all LOINC codes

MedDRA LLT

FHIR ValueSet for MedDRA LLT 26.0

List of MedDRA codes suitable for use in New Zealand

This value set includes the codes from SNOMED CT that are included in: descendants of 373873005 |Pharmaceutical / biologic product (product)|, excluding the descendants of 787859002 |Vaccine product (medicinal product)|, plus IPS codes for absent/unknown medications.

EDQM (European Directorate for the Quality of Medicines and Healthcare) Dose Form codes. This Value Set includes all the EDQM Standard Terms having:
[Concept Status] = ‘Current’ AND
[Concept Class] IN (‘PDF’, ‘CMT’, ‘CDF’, ‘PFT’) AND
[Domain] = ‘Human and Veterinary’

PDF = ‘Pharmaceutical dose form’; CMT = ‘Combined terms’; CDF = ‘Combined pharmaceutical dose form’; PFT = ‘Patient Friendly’

EDQM (European Directorate for the Quality of Medicines and Healthcare) Route of Administration codes. This Value Set includes all the EDQM Standard Terms having:
[Concept Status] = ‘Current’ AND
[Concept Class] = ‘ROA’ AND
[Domain] = ‘Human and Veterinary’

ROA = ‘Route of administration’

A clinical regional lymph node stage (cN) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The clinical stage groups that describe how far a breast cancer has grown and spread before initiation of treatment, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a breast tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a breast tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a breast tumour, using the AJCC cancer staging manual (8th edition).

The pathological stage groups that describe how far a breast cancer has grown and spread using information obtained from pathological examination of tissue samples, using AJCC cancer staging manual (8th edition).

AJCC (8th edition) residual tumour (R) category.

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a cervix uteri tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a cervix uteri tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri adenosarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri adenosarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a corpus uteri adenosarcoma, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri adenosarcoma, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a corpus uteri adenosarcoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri carcinoma and/or carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a corpus uteri carcinoma and/or carcinosarcoma, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri carcinoma and/or carcinosarcoma, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a corpus uteri carcinoma and/or carcinosarcoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a corpus uteri tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a corpus uteri tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a corpus uteri tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a corpus uteri tumour, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a gestational trophoblastic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gestational trophoblastic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a gestational trophoblastic cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a ovary, fallopian tube and/or primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a ovary, fallopian tube and/or primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a ovary, fallopian tube and/or primary peritoneal carcinoma, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a ovary, falliopian and/or primary peritoneal carcinoma, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a ovary, fallopian tube and/or primary peritoneal carcinoma, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a ovary, fallopian tube and/or peritoneal carcinoma has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a female genital tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a female genital tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a female genital tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a female genital cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a vagina tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a vagina tumour, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a vulva tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a vulva cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The clinical stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 20 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A post therapy or post neoadjuvant therapy pathological tumour stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

The pathological stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a gastrointestinal stromal tumour (GIST) gastric and/or omental has grown and spread, using chapter 43.1 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a gastrointestinal stromal tumour (GIST) before initiation of treatment, using chapter 43 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a gastrointestinal stromal tumour (GIST) small intestine and/or oesophageal and/or colon and/or rectum and/or mesenteric and/or peritoneal has grown and spread, using chapter 43.1 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a Hodgkin or non Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

The stage groups that describe how far a chronic lymphocytic lymphoma or a small lymphocytic lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome), using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a mycosis fungoides or sezary syndrome has grown and spread, using AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a haematologic cancer, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a haematologic cancer, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a haematologic cancer, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a paediatric Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

The stage groups that describe how far a paediatric non Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome), using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a cutaneous B cell or T cell lymphoma (non mycosis fungoides and non sezary syndrome), using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestinal colon and/or rectum tumour before initiation of treatment, using chapter 33 of the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a neuroendocrine gastrointestinal colon and/or rectum cancer has grown and spread, using chapter 33 of the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestinal tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a neuroendocrine gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a lung tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a lung tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a lung cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a thoracic tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a thoracic tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a thoracic tumour, using the AJCC cancer staging manual (8th edition).

The stage groups that describe how far a thoracic cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical regional lymph node stage (cN) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A clinical tumour stage (cT) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (8th edition).

A pathological distant metastasis stage (pM) of a thymus tumour, using the AJCC cancer staging manual (8th edition).

A pathological regional lymph node stage (pN) of a thymus tumour, using the AJCC cancer staging manual (8th edition).

A pathological tumour stage (pT) of a thymus tumour, using the AJCC cancer staging manual (8th edition).

The stage group that describe how far a thymus cancer has grown and spread, using AJCC cancer staging manual (8th edition).

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical regional lymph node stage (cN) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical tumour stage (cT) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological distant metastasis stage (pM) of a cervix uteri tumour, using the AJCC cancer staging manual (9th edition).

A pathological regional lymph node stage (pN) of a cervix uteri tumour, using the AJCC cancer staging manual (9th edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (9th edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (9th edition).

A clinical distant metastasis stage (cM) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical regional lymph node stage (cN) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A clinical tumour stage (cT) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological distant metastasis stage (pM) of a female genital tumour, using the AJCC cancer staging manual (9th edition).

A pathological regional lymph node stage (pN) of a female genital tumour, using the AJCC cancer staging manual (9th edition).

A pathological tumour stage (pT) of a female genital tumour, using the AJCC cancer staging manual (9th edition).

The stage groups that describe how far a female genital cancer has grown and spread, using AJCC cancer staging manual (9th edition).

A clinical distant metastasis stage (cM) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (9th edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (9th edition).

Residual tumour values on structured pathology request form (surgeon) to remove R1 - Microscopic residual tumour based on AJCC 8th edition.

A clinical distant metastasis stage (cM) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a breast tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a breast tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a breast tumour, using the AJCC cancer staging manual (latest edition).

The anatomic and prognostic stage groups that describe how far a breast cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A numbered edition of the AJCC (AJCC)’s cancer staging system.

A clinical distant metastasis stage (cM) before initiation of treatment, using the AJCC cancer staging manual.

A clinical regional lymph node stage (cN) before initiation of treatment, using the AJCC cancer staging manual.

A clinical tumour stage (cT) of a tumour before initiation of treatment, using the AJCC cancer staging manual.

The clinical stage groups that describe how far a cancer has grown and spread before initiation of treatment, using AJCC cancer staging manual.

A clinical distant metastasis stage (cM) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a cervix uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a cervix uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a cervix uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a cervix uteri tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a cervix uteri cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a female genital tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri adenosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a corpus uteri adenosarcoma, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a corpus uteri adenosarcoma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri carcinoma and/or carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri carcinoma and/or carcinosarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a corpus uteri carcinoma and/or carcinosarcoma, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri carcinoma and/or carcinosarcoma, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a corpus uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a corpus uteri leimyosarcoma and/or endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri leiomyosarcoma and/or endometrial stromal sarcoma, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a corpus uteri tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a corpus uteri cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a gestational trophoblastic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gestational trophoblastic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a gestational trophoblastic tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a gestational trophoblastic cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a ovary, fallopian tube and/or primary peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a ovary, fallopian tube and/or peritoneal carcinoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a ovary, fallopian tube and/or primary peritoneal carcinoma, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a ovary, falliopian and/or primary peritoneal carcinoma, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a ovary, fallopian tube and/or peritoneal carcinoma has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a female genital tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a female genital tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a female genital cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a vagina tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a vagina tumour, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a vulva tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a vulva tumour, using the AJCC cancer staging manual (latest edition).

The stage group that describe how far a vulva cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a gastrointestional colon and/or rectum tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a gastrointestinal colon and/or rectum cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A post therapy or post neoadjuvant therapy pathological tumour stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual.

The pathogical stage group that describe how far a gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a gastrointestinal stromal tumour (GIST) gastric and/or omental has grown and spread, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a gastrointestional stromal tumour (GIST) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a gastrointestinal stromal tumour (GIST) small intestine and/or oesophageal and/or colon and/or rectum and/or mesenteric and/or peritoneal has grown and spread, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a Hodgkin or non-Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

The stage groups that describe how far a chronic lymphocytic lymphoma or a small lymphocytic lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a haematologic cancer before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome), using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a mycosis fungoides or sezary syndrome cutaneous lymphoma, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a mycosis fungoides or sezary syndrome has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a haematologic cancer, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a paediatric Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

The stage groups that describe how far a paediatric non-Hodgkin lymphoma has grown and spread, using AJCC cancer staging manual (latest edition).

The stage groups that describe how far a plasma cell myeloma has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome) before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a cutaneous B cell or T cell lymphoma (non Mycosis fungoides and non-sezary syndrome), using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a haematologic cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestional colon and/or rectum tumour before initiation of treatment, the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a neuroendocrine gastrointestional tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a neuroendocrine gastrointestinal cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM), using the AJCC cancer staging manual.

A pathological regional lymph node stage (pN), using the AJCC cancer staging manual.

A pathological tumour stage (pT) of a tumour, using the AJCC cancer staging manual.

The pathological stage groups that describe how far a cancer has grown and spread using information obtained from pathological examination of tissue samples, using AJCC cancer staging manual.

A post therapy or post neoadjuvant therapy clinical tumour stage (ycT) of a tumour, using the AJCC cancer staging manual.

A post therapy or post neoadjuvant therapy pathological regional lymph node stage (ypN) using the AJCC cancer staging manual.

A post therapy or post neoadjuvant therapy pathological tumour stage (ypT) of a tumour, using the AJCC cancer staging manual.

The post therapy or post neoadjuvant pathological stage groups that describe how far a cancer has grown and spread using information obtained from pathological examination of tissue samples, using AJCC cancer staging manual.

A recurrence or retreatment clinical regional lymph node stage (rcN) before initiation of treatment, using the AJCC cancer staging manual.

A recurrence or retreatment clinical tumour stage (rcT) of a tumour, using the AJCC cancer staging manual.

A recurrence or retreatment pathological distant metastasis stage (pM), using the AJCC cancer staging manual.

A recurrence or retreatment pathological regional lymph node stage (rpN), using the AJCC cancer staging manual.

A recurrence or retreatment pathological tumour stage (pT) of a tumour, using the AJCC cancer staging manual.

A clinical distant metastasis stage (cM) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a thoracic tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a lung tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a lung tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a lung tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a lung tumour, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a malignant pleural mesothelioma tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a malignant pleural mesothelioma tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a malignant pleural mesothelioma cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a thoracic tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a thoracic tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a thoracic tumour, using the AJCC cancer staging manual (latest edition).

The stage groups that describe how far a thoracic cancer has grown and spread, using AJCC cancer staging manual (latest edition).

A clinical distant metastasis stage (cM) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical regional lymph node stage (cN) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A clinical tumour stage (cT) of a thymus tumour before initiation of treatment, using the AJCC cancer staging manual (latest edition).

A pathological distant metastasis stage (pM) of a thymus tumour, using the AJCC cancer staging manual (latest edition).

A pathological regional lymph node stage (pN) of a thymus tumour, using the AJCC cancer staging manual (latest edition).

A pathological tumour stage (pT) of a thymus tumour, using the AJCC cancer staging manual (latest edition).

Citizenship status

The grade of a breast cancer, assessed using the Nottingham combined grading system.

A coded type for the source of information for NZ residency

Is the person a NZ resident

A diagnosis of whether or not a tumour is estrogen receptive (ER) minus inconculsive value.

A diagnosis of the human epidermal growth factor receptor 2 (HER2) status of a tumour minus inconculsive value .

A diagnosis of whether or not a tumour is progesterone receptive (PR) minus inconculsive value.

Types of responses to an acute lymphoblastic leukaemia systemic anti-cancer therapy (SACT) treatment.

Types of responses to an acute myeloid leukaemia systemic anti-cancer therapy (SACT) treament.

Types of responses to an amyloidosis systemic anti-cancer therapy (SACT) treatment.

Types of evidence that may be used to reach a cancer diagnosis, which is treated with systemic anti cancer therapy (SACT).

The type of primary cancer being assessed, by systemic anti-cancer therapy (SACT).

Types of responses to a chronic lymphocytic leukaemia and/or small lymphocytic lymphoma systemic anti-cancer therapy (SACT) treatment.

Types of responses to a chronic myeloid leukaemia systemic anti-cancer therapy (SACT) treatment.

Reasons for adjusting the dose of a systemic anti-cancer therapy (SACT) treatment cycle plus other value.

Dose forms in which a systemic anti-cancer therapy (SACT) medication may be prescribed or administered.

Units that may be used to describe the dose of a systemic anti-cancer therapy (SACT) medication.

Types of responses to a non small lymphocytic systemic anti-cancer therapy (SACT) treatment.

Types of responses to a medical oncology systemic anti-cancer therapy (SACT) treatment.

Types of responses to a myelodysplastic syndrome systemic anti-cancer therapy (SACT) treatment.

Types of responses to a myeloma systemic anti-cancer therapy (SACT) treatment.

Overall reasons that a systemic anti-cancer therapy (SACT) regimen may be discontinued plus other value.

Patient factors that may result in the discontinuation of a systemic anti-cancer therapy (SACT) treatment plus not asked value.

Systemic anti-cancer therapy (SACT) regimens published by the New Zealand Medicines Formulary in the SACT Regimen Library.

Routes by which a systemic anti-cancer therapy (SACT) medication may be administered to a patient.

TNM stage classification used to define timing of staging at timepoints post surgery.

TNM stage classification used to define timing of staging.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) central nervous system tumour grading system.

A subset of the maximal differentiation grading reference set (excluding G4; undifferentiated grade), described by World Health Organization (5th edition).

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) malignant differentiation grading system.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) malignant low / high grading system.

The grade of a cancer, assessed using the WHO Classification of Tumours (5th edition) neuroendocrine tumour grading system.

Histologies used for anal neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 7. Tumours of the anal canal, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for appendix primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix, 12. Mesenchymal tumours of the digestive system or an ‘Other’ value.

Histologies used for appendix neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix,11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system or an ‘Other’ value.

Histologies used for biliary tract primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 9. Tumours of the gallbladder and extrahepatic bile ducts 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an ‘Other’ value.

Histologies used for biliary tract neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 9. Tumours of the gallbladder and extrahepatic bile ducts, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an ‘Other’ value.

Histologies used for bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 4. Bone tumours) or an ‘Other’ value.

Histologies used for bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, 5th edition - 4. Bone tumours) or an ‘Other’ value.

Histologies used for bone primaries, from WHO Classification of Tumours, Soft Tissue & Bone Tumours (latest edition) - 3. Undifferentiated small round cell sarcomas of bone and soft tissue, 4. Bone tumours or an ‘Other’ value.

Histologies used for behaviour free breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for benign breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for benign breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for in situ carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for in situ carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 2. Epithelial tumours of the breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 3. Fibroepithelial tumours and hamartomas of the breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 3. Fibroepithelial tumours and hamartomas of the breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 6. Haematolymphoid tumours of the breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for invasive carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for invasive carcinoma breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for invasive breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for invasive breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 5. Mesenchymal tumours of the breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 5. Mesenchymal tumours of the breast) or an ‘Other’ value.

Histologies used for neuroendocrine breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for breast primaries (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 2. Epithelial tumours of the breast, 3. Fibroepithelial tumours and hamartomas of the breast, 4. Tumours of the nipple, 5. Mesenchymal tumours of the breast, 7. Tumours of the male breast or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 4. Tumours of the nipple) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 4. Tumours of the nipple) or an ‘Other’ value.

Histologies used for uncertain and/or borderline breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition) or an ‘Other’ value.

Histologies used for uncertain and/or borderline breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition) or an ‘Other’ value.

The grade of a cancer, assessed using the WHO Classification of Tumours central nervous system tumour grading system.

Histologies used for intestinal T-cell AND/OR natural killer cell lymphoid proliferation (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for colorectal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 6. Tumours of the colon and rectum, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for colorectal neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 6. Tumours of the colon and rectum, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 7. Tumours of the anal canal or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 7. Tumours of the anal canal or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 5. Tumours of the appendix or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 5. Tumours of the appendix or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 6. Tumours of the colon and rectum or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours) 6. Tumours of the colon and rectum. Neuroendocrine tumour hormone producing subtype or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 6. Tumours of the colon and rectum. Neuroendocrine tumour hormone producing subtype or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 13. Other digestive system, germ cell tumour or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 13. Other digestive system, germ cell tumour or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 11. Haematolymphoid tumours of the digestive system

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 11. Haematolymphoid tumours of the digestive system or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours) Neuroendocrine tumour hormone producing subtype or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) Neuroendocrine tumour hormone producing subtype or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 8. Tumours of the liver and intrahepatic bile ducts or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 8. Tumours of the liver and intrahepatic bile ducts or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 13. Other digestive system, muscosal melanoma or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 13. Other digestive system, muscosal melanoma or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 2. Tumours of the oesophagus or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 10. Tumours of the pancreas or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 10. Tumours of the pancreas or an ‘Other’ value.

Histologies used for digestive system cancer types excluding heamatological histologies (WHO Classification of Tumours, Digestive System Tumours, latest edition) or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, latest edition) 4. Tumours of the small intestine and ampulla or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 4. Tumours of the small intestine and ampulla or an ‘Other’ value.

Histologies used for digestive system cancer types (WHO Classification of Tumours, Digestive System Tumours, 5th edition) 3. Tumours of the stomach or an ‘Other’ value.

Histologies used for fallopian tube primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 5. Tumours of the fallopian tube, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an ‘Other’ value.

Histologies used for fallopian tube sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 5. Tumours of the fallopian tube, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an ‘Other’ value.

Histologies used for female breast primaries, except for the nipple (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 2. Epithelial tumours of the breast, 3. Fibroepithelial tumours and hamartomas of the breast, 5. Mesenchymal tumours of the breast or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 5. Tumours of the fallopian tube) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 5. Tumours of the fallopian tube) or an ‘Other’ value.

Histologies used for female genital germ cell tumours (WHO Classification of Tumours, Female Genital Tumours, latest edition) or an ‘Other’ value.

Histologies used for female genital germ cell tumours (WHO Classification of Tumours, Female Genital Tumours, 5th edition) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 8. Gestational trophoblastic disease) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 13. Haematolymphoid proliferations and neoplasia) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 13. Haematolymphoid proliferations and neoplasia) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 15. Melanocytic lesions) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 15. Melanocytic lesions) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 14. Mesenchymal tumours of lower genital tract) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 14. Mesenchymal tumours of lower genital tract) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 12. Neuroendocrine neoplasia) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 12. Neuroendocrine neoplasia) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 2. Tumours of the ovary) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 2. Tumours of the ovary) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 4. Tumours of the peritoneum) or an ‘Other’ value.

Histologies used for female genital primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 2. Tumours of the ovary, 4. Tumours of the peritoneum, 5. Tumours of the fallopian tube, 6. Tumours of the broad ligament and other uterine ligaments, 7. Tumours of the uteine corpus, 8. Gestational trophoblastic disease, 9. Tumours of the uterine cervix, 10. Tumours of the vagina, 11. Tumours of the vulva, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 9. Tumours of the uterine cervix) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 9. Tumours of the uterine cervix) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 7. Tumours of the uterine corpus) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 7. Tumours of the uterine corpus) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 6. Tumours of the broad ligament and other uterine ligaments) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 10. Tumours of the vagina) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 10. Tumours of the vagina) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, latest edition - 11. Tumours of the vulva) or an ‘Other’ value.

Histologies used for female genital cancer types (WHO Classification of Tumours, Female Genital Tumours, 5th edition - 11. Tumours of the vulva) or an ‘Other’ value.

Histologies used for gestational trophoblastic primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 8. Gestational trophoblastic disease, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for chronic myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for chronic myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th editions) or an ‘Other’ value.

Histologies used for B cell lymphoid proliferations and lymphomas (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 4. B cell lymphoid proliferations and lymphomas) or an ‘Other’ value.

Histologies used for B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for B lymphoblastic leukaemia lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for B lymphoblastic leukaemia lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for Burkitt lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for Burkitt lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for Hodgkin lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for Hodgkin lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for T cell and NK cell lymphoid proliferations and lymphomas (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 5. T cell and NK cell lymphoid proliferations and lymphomas) or an ‘Other’ value.

Histologies used for t lymphoblastic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for T lymphoblastic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for T-cell AND/OR natural killer cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for acute leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for acute leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for acute leukaemia of mixed or ambiguous lineage (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for acute leukaemia of mixed or ambiguous lineage (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for acute lymphoblastic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for acute lymphoblastic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for acute myeloid leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for acute myeloid leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for aggressive B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for aggressive non-Hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for aggressive non-hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for aggressive non-hodgkin B cell lymphoma not primary CNS or Burkitts or mediastinal lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for amyloidosis (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for chronic eosinophilic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for chronic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for chronic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for chronic lymphocytic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for chronic lymphocytic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for chronic lymphocytic leukaemia/small lymphocytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for chronic myeloid leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for chronic myeloid leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for chronic neutrophilic leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for cutaneous mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for dendritic cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for dendritic cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for diffuse large B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for diffuse large B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for essential thrombocythemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for essential thrombocythemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for extranodal NK cell and T cell lymphoid proliferation (WHO Classification of Tumours, Haematolymphoid Tumours,latest edition) or an ‘Other’ value.

Histologies used for extranodal NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for extranodal NK cell and T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for follicular lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for follicular lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for hairy cell leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for histiocytic and dendritic cell neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 3. Histiocytic/Dendritic cell neoplasms) or an ‘Other’ value.

Histologies used for indolent B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for other indolent B cell lymphoma not Chronic lymphocytic leukaemia and/or small lymphocytic lymphoma, Monoclonal B cell lymphocytosis, Hairy cell leukaemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinaemia), Marginal zone lymphoma or Follicular lymphoma Mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for indolent non-Hodgkin B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for other indolent non-hodgkin B cell lymphoma not Chronic lymphocytic leukaemia and/or small lymphocytic lymphoma, Monoclonal B cell lymphocytosis, Hairy cell leukaemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinaemia), Marginal zone lymphoma or Follicular lymphoma Mantle cell lymphoma(WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for leukaemia (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for lymphoplasmacytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for lymphoplasmacytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for mantle cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for marginal zone lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for marginal zone lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for mastocytosis which are not systemic or cutaneous or mast cell sarcoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for mature T cell and/or natural killer cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for mature T cell and/or natural killer cell neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for mature T-cell AND/OR natural killer cell neoplasm not peripheral T cell or extranodal NK/T cell or primary T cell cutaneous lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for mediastinal large B cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for myelodysplastic and myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for myelodysplastic and myeloproliferative neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for myelodysplastic and myeloproliferative neoplasm not chronic myelomonocytic leukemia (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for myelodysplastic syndrome (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for myeloid precursor lesion (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for myeloid precursor lesion (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 2. Myeloid proliferations and neoplasms) or an ‘Other’ value.

Histologies used for myeloid/lymphoid neoplasm with eosinophilia and defining gene rearrangement (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for myeloid/lymphoid neoplasm with eosinophilia and defining gene rearrangement (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for myeloma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for myeloproliferative neoplasm which are not primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukaemia, chronic eosinophilic leukaemia, juvenile myelomonocytic leukaemia, (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for non Hodgkin lymphoma (WHO Classification of tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for non-Hodgkin lymphoma (WHO Classification of tumours, Haematolymphoid Tumours, latest edition)

Histologies used for peripheral T cell lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for plasma cell neoplasms and/or other diseases with paraproteins (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for plasma cell neoplasms and/or other diseases with paraproteins (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for polycythemia vera (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for polycythemia vera (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for primary central nervous system lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for primary central nervous system lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for primary cutaneous T cell lymphoproliferative disorder (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for primary myelofibrosis (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for primary myelofibrosis (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for small lymphocytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition)

Histologies used for small lymphocytic lymphoma (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition)

Histologies used for stroma-derived neoplasms of lymphoid tissues (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition - 6. Stroma-derived neoplasms of lymphoid tissues) or an ‘Other’ value.

Histologies used for systemic mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for systemic mastocytosis (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for haematolymphoid cancer types (WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition) or an ‘Other’ value.

Histologies used for heart primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 4. Tumours of the heart, 5. Mesenchymal tumours of the thorax, 7. Germ cell tumours of the mediastinum and 9. Ectopic tumours of thyroid and parathyroid origin) or an ‘Other’ value.

Histologies used for B cell lymphoid proliferations and lymphomas (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 4. B cell lymphoid proliferations and lymphomas) or an ‘Other’ value.

Histologies used for histiocytic and dendritic cell neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 3. Histiocytic/Dendritic cell neoplasms) or an ‘Other’ value.

Histologies used for myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 2. Myeloid proliferations and neoplasms) or an ‘Other’ value.

Histologies used for stroma-derived neoplasms of lymphoid tissues (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition - 6. Stroma-derived neoplasms of lymphoid tissues) or an ‘Other’ value.

Histologies used for haematolymphoid cancer types (WHO Classification of Tumours, Haematolymphoid Tumours, latest edition) or an ‘Other’ value.

Histologies used for hepatopancreaticobiliary primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 8. Tumours of the liver and intrahepatic bile ducts, 9. Tumours of the gallbladder and extrahepatic bile ducts, 10. Tumours of the pancreas, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an ‘Other’ value.

Histologies used for any cancer type (WHO Classification of Tumours, latest editions) or an ‘Other’ value.

Histologies used for kidney primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for kidney sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for liver primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 8. Tumours of the liver and intrahepatic bile ducts,12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an ‘Other’ value.

Histologies used for liver neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 8. Tumours of the liver and intrahepatic bile ducts, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Germ cell tumours only)) or an ‘Other’ value.

Histologies used for lower gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix, 6. Tumours of the colon and rectum, 7. Tumours of the anal canal, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for lower gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 5. Tumours of the appendix, 6. Tumours of the colon and rectum, 7. Tumours of the anal canal, 11. Haematolymphoid tumours of the digestive system 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for lung primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 2. Tumours of the lung and 5. Mesenchymal tumours of the thorax) or an ‘Other’ value.

Histologies used for lung neoplasms (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 2. Tumours of the lung and 5. Mesenchymal tumours of the thorax) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, latest edition - 7. Tumours of the male breast) or an ‘Other’ value.

Histologies used for breast cancer types (WHO Classification of Tumours, Breast Tumours, 5th edition - 7. Tumours of the male breast) or an ‘Other’ value.

Histologies used for male breast primaries, except for the nipple (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 3. Fibroepithelial tumours and hamartomas of the breast, 5. Mesenchymal tumours of the breast, 7. Tumours of the male breast or an ‘Other’ value.

Histologies used for male breast primaries (excluding benign), from WHO Classification of Tumours, Breast Tumours (latest edition) - Sections 3. Fibroepithelial tumours and hamartomas of the breast, 4. Tumours of the nipple, 5. Mesenchymal tumours of the breast, 7. Tumours of the male breast or an ‘Other’ value.

Histologies used for male genital primary, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 6. Tumours of the testis, 7. Tumours of the testicular adnexa, 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for male genital sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 6. Tumours of the testis, 7. Tumours of the testicular adnexa, 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

A subset of the maximal differentiation grading reference set (excluding G4; undifferentiated grade), described by World Health Organization.

Histologies used for any medical oncology cancer site (WHO Classification of Tumours, latest editions) or an ‘Other’ value.

Histologies used for any medical oncology primary type (WHO Classification of Tumours, latest editions) or an ‘Other’ value.

The grade of a cancer, assessed using the WHO Classification of Tumours neuroendocrine tumour grading system.

Histologies used for oesophagus primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for oesophagus neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for ovarian germ cell primaries (from WHO Classification of Tumours, Female Genital Tumours, latest edition) or an ‘Other’ value.

Histologies used for ovary sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 2. Tumours of the ovary, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an ‘Other’ value.

Histologies used for pancreatic primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 10. Tumours of the pancreas,12. Mesenchymal tumours of the digestive system) or an ‘Other’ value.

Histologies used for pancreatic neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 10. Tumours of the pancreas, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system) or an ‘Other’ value.

Histologies used for penis primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for penis sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for pericardium neoplasms (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium, 5. Mesenchymal tumours of the thorax, 7. Germ cell tumours of the mediastinum, 8. Haematolymphoid tumours of the mediastinum, and 9. Ectopic tumours of thyroid and parathyroid origin) or an ‘Other’ value.

Histologies used for peritoneum primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 4. Tumours of the peritoneum, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for peritoneum sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 4. Tumours of the peritoneum, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an ‘Other’ value.

Histologies used for pleural primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium (excluding haematolymphoid tumours) and 5. Mesenchymal tumours of the thorax) or an ‘Other’ value.

Histologies used for pleural neoplasms (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 3. Tumours of the pleura and pericardium and 5. Mesenchymal tumours of the thorax) or an ‘Other’ value.

Histologies used for prostate primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for prostate sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for renal pelvis and/or ureter sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for small intestine primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 4. Tumours of the small intestine and ampulla,, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for small intestine neoplasms(from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 4. Tumours of the small intestine and ampulla, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for soft tissue and/or bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition) or an ‘Other’ value.

Histologies used for soft tissue and/or bone primaries, from WHO Classification of Tumours, Soft Tissue & Bone Tumours (latest edition) - 2. Soft tissue tumours, 3. Undifferentiated small round cell sarcomas of bone and soft tissue, 4. Bone tumours or an ‘Other’ value.

Histologies used for soft tissue and/or bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 3. Undifferentiated small round cell sarcoma of bone and soft tissue) or an ‘Other’ value.

Histologies used for soft tissue and/or bone cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, 5th edition - 3. Undifferentiated small round cell sarcoma of bone and soft tissue) or an ‘Other’ value.

Histologies used for soft tissue cancer types (WHO Classification of Tumours, Soft Tissue & Bone Tumours, latest edition - 2. Soft tissue tumours) or an ‘Other’ value.

Histologies used for soft tissue sites, from WHO Classification of Tumours, Soft Tissue & Bone Tumours (latest edition) - 2. Soft tissue tumours, 3. Undifferentiated small round cell sarcomas of bone and soft tissue or an ‘Other’ value.

Histologies used for stomach primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 3. Tumours of the stomach,12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for stomach neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 3. Tumours of the stomach, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for testicular adnexa primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 7. Tumours of the testicular adnexa, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for testicular adnexa sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 7. Tumours of the testicular adnexa, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for testicular other primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) or an ‘Other’ value.

Histologies used for testicular seminoma primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) or an ‘Other’ value.

Histologies used for testies primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 6. Tumours of the testis, 9. Neuroendocrine neoplasms, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for testies sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 6. Tumours of the testis, 9. Neuroendocrine neoplasms, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 9. Ectopic tumours of thyroid and parathyroid origin or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 4. Tumours of the heart or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 4. Tumours of the heart or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 2. Tumours of the lung or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 2. Tumours of the lung or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 7. Germ cell tumours of the mediastinum or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 8. Haematolymphoid tumours of the mediastinum

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 8. Haematolymphoid tumours of the mediastinum or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 5. Mesenchymal tumours of the thorax or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 2. Tumours of the lung. Non small cell histology or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 2. Tumours of the lung. Non small cell histology or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 3. Tumours of the pleura and pericardium or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 2. Tumours of the lung. Small cell histology or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, 5th edition) 2. Tumours of the lung. Small cell histology or an ‘Other’ value.

Histologies used for thoracic cancer types (WHO Classification of Tumours, Thoracic Tumours, latest edition) 6. Tumours of the thymus or an ‘Other’ value.

Histologies used for thymus primaries (from WHO Classification of Tumours, Thoracic Tumours, latest edition, including sections 5. Mesenchymal tumours of the thorax, 6. Tumours of the thymus, 7. Germ cell tumours of the mediastinum and 9. Ectopic tumours of thyroid and parathyroid origin) or an ‘Other’ value.

Histologies used for upper gastrointestinal primaries (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 3. Tumours of the stomach, 4. Tumours of the small intestine and ampulla, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for upper gastrointestinal neoplasms (from WHO Classification of Tumours, Digestive Tumours, latest edition, including sections 2. Tumours of the oesophagus, 3. Tumours of the stomach, 4. Tumours of the small intestine and ampulla, 11. Haematolymphoid tumours of the digestive system, 12. Mesenchymal tumours of the digestive system, 13. Other tumours of the digestive system (Melanoma only)) or an ‘Other’ value.

Histologies used for urethra primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urethra sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 11. Haematolymphoid tumours) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 11. Haematolymphoid tumours) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 2. Tumours of the kidney) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 2. Tumours of the kidney) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 12. Melanocytic lesions) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 12. Melanocytic lesions) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 10. Mesenchymal tumours) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 10. Mesenchymal tumours) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 9. Neuroendocrine neoplasms) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 9. Neuroendocrine neoplasms) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 8. Tumours of the penis and scrotum) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 8. Tumours of the penis and scrotum) or an ‘Other’ value.

Histologies used for urinary and male genital primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 3. Tumours of the urinary tract, 4. Tumours of the prostate, 5. Tumours of the seminal vesicle, 6. Tumours of the testis, 7. Tumours of the testicular adnexa, 8. Tumours of the penis and scrotum, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 4. Tumours of the prostate) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 4. Tumours of the prostate) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 5. Tumours of the seminal vesicle) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 5. Tumours of the seminal vesicle) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 7. Tumours of the tesicular adnexa) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 7. Tumours of the tesicular adnexa) or an ‘Other’ value.

Histologies used for germ cell tumours of testis (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 6. Tumours of the testis) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 6. Tumours of the testis) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, latest edition - 3. Tumours of the urinary tract) or an ‘Other’ value.

Histologies used for urinary and male genital cancer types (WHO Classification of Tumours, Urinary & Male Genital Tumours, 5th edition - 3. Tumours of the urinary tract) or an ‘Other’ value.

Histologies used for urinary bladder primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urinary bladder sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urinary system primaries, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for urinary system sites, from WHO Classification of Tumours, Urinary & Male Genital Tumours (latest edition) - Sections 2. Tumours of the kidney, 3. Tumours of the urinary tract, 9. Neuroendocrine neoplasms, 10. Mesenchymal tumours, 11. Haematolymphoid tumours, 12. Melanocytic lesions or an ‘Other’ value.

Histologies used for uterine cervix primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 9. Tumours of the uterine cervix, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for uterine cervix sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 9. Tumours of the uterine cervix, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions, Endometriosis or an ‘Other’ value.

Histologies used for uterine corpus primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 7. Tumours of the uterine corpus, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for uterine corpus sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 7. Tumours of the uterine corpus, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for uterine ligament primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 6. Tumours of the broad ligament and other uterine ligaments, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for uterine ligament sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 6. Tumours of the broad ligament and other uterine ligaments, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for vagina primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 10. Tumours of the vagina, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for vagina sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 10. Tumours of the vagina, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for vulva primaries, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 11. Tumours of the vulva, 12. Neuroendocrine neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

Histologies used for vulva sites, from WHO Classification of Tumours, Female Genital Tumours (latest edition) - Sections 11. Tumours of the vulva, 12. Neuroendocrine neoplasia, 13. Haematolymphoid proliferations and neoplasia, 14. Mesenchymal tumours of the lower genital tract, 15. Melanocytic lesions or an ‘Other’ value.

The stage groups for lymphoma, defined using Ann Arbor staging system.

The type of B cell lymphoid haematologic cancer being assessed and/or treated.

The type of B cell lymphoma haematologic cancer being assessed and/or treated.

The prognostic score for Burkitt lymphoma, defined using the Burkitt Lymphoma International Prognostic Index (BL-IPI) scoring system..

The stage groups for chronic lymphocytic leukaemia, defined using Binet staging system.

The type of the primary central nervous system (CNS) solid cancer being assessed and/or treated.

The prognostic score for reporting status in acute lymphoblastic lymphoma, defined using the central nervous system (CNS) prognostic scoring system.

The prognostic score for large B-cell lymphoma, defined using the Central Nervous System International Prognostic Index (CSN-IPI) scoring system.

The prognostic score for myelofibrosis, defined using the Dynamic International Prognostic Scoring System Plus (DIPSS+).

The performance status of a patient as defined by the Eastern Cooperative Oncology Group (ECOG).

The prognostic score for reporting genetic alteration in acute myeloid leukaemia, defined using the European LeukemiaNet (ELN) prognostic scoring system.

An assessment of whether or not a tumour is estrogen receptive (ER).

The prognostic score for chronic myeloid leukaemia, defined using the European Treatment and Outcome Study (EUTOS) prognostic scoring system.

The stage groups for a gestational trophoblastic tumour, defined by International Federation of Gynecology and Obstetrics 2001 staging system.

The grade of an endometrial carcinoma, assessed using the International Federation of Gynecology and Obstetrics 2009 grading system.

The stage groups for a ovary, fallopian tube and/or primary peritoneal carcinoma, defined by International Federation of Gynecology and Obstetrics 2014 staging system.

The stage groups for a cervix uteri tumour, defined by International Federation of Gynecology and Obstetrics 2018 staging system.

The stage groups for a vagina tumour, defined by International Federation of Gynecology and Obstetrics 2018 staging system.

The stage groups for a vulva tumour, defined by International Federation of Gynecology and Obstetrics 2021 staging system.

The prognostic score for follicular lymphoma, defined using the Follicular Lymphoma International Prognostic Scoring (FLIPI) system.

The stage groups for Hodgkin lymphoma, defined using German Hodgkin Study Group (GHSG) staging system.

An assessment of the human epidermal growth factor receptor 2 (HER2) status of a tumour.

The prognostic score for a cancer, defined by International Extranodal Lymphoma Study Group (IELSG) prognostic scoring system.

The prognostic score for Waldenstrom Macroglobulinemia, defined using the International Scoring System for Waldenstrom Macroglobulinemia (IPSSWM).

The prognostic score for myelodysplastic syndrome, defined using the Molecular International Prognostic Scoring System (IPSS-M).

The prognostic score for myelodysplastic syndrome, defined using the Revised International Prognostic Scoring System (IPSS-R).

The prognostic score for thrombosis in essential thrombocythemia, defined using the International Prognostic Score (IPS) system.

The neoadjuvant therapy response score for breast, defined using the MD Anderson residual cancer burden system.

The prognostic score for mantle cell lymphoma, defined using the Mantle Cell Lymphoma International Prognostic Scoring (MIPI) system.

The stage groups for amyloidosis, defined using Mayo staging system.

The stage groups for NK-cell and/or T-cell lymphoma, defined using non-Hodgkin lymphoma treatment stratification staging system.

Test method procedures used in laboratory studies.

The prognostic score for T-cell lymphoma, defined using the Prognostic Index for T-cell Lymphoma (PIT) prognostic scoring system.

An assessment of whether or not a tumour is progesterone receptive (PR).

The stage groups for multiple myeloma, defined using Revised International Staging System (R-ISS).

The stage groups for chronic lymphocytic leukaemia, defined by Rai staging system.

The prognostic score for chronic myeloid leukaemia, defined using the Sokal index prognostic scoring system.

The type of T/ NK cell lymphoid haematologic cancer being assessed and/or treated.

The type of T/NK cell lymphoma haematologic cancer being assessed and/or treated.

The type of acute leukaemia haematologic cancer being assessed and/or treated.

Whether or not it has been identified that the tumour has invaded into adjacent organs

The type of aggressive non-Hodgkin B cell lymphoma haematologic cancer being assessed and/or treated.

Types of evidence that may be used to reach a cancer diagnosis.

Body sites used as landmarks for procedures or an ‘Other’ value.

The type of the primary bone solid cancer being assessed and/or treated.

The body location used to describe the point of origin for other bone cancer or an ‘Other’ value.

Lymph nodes used for diagnosis of breast cancer or an ‘Other’ value.

The body location used to describe the point of origin for nipple-areola complex breast cancer or an ‘Other’ value.

The body location used to describe the point of origin for brain cancer or an ‘Other’ value.

The body location used to describe the point of origin for meninges cancer or an ‘Other’ value.

The body location used to describe the point of origin for nerve cancer of the central nervous system or an ‘Other’ value.

The body location used to describe the point of origin for other central nervous system cancer or an ‘Other’ value.

The body location used to describe the point of origin for spinal cord cancer or an ‘Other’ value.

The body location used to describe the point of origin for central nervous system cancer or an ‘Other’ value.

The type of the primary colorectal solid cancer being assessed and/or treated.

Body sites that are accessed by a surgeon during a colorectal metastectomy procedure

The completion status of the procedure and/or test.

A reason that no specific value is available.

The result for a test (eg detected, not detected), where more specific finding values are not available.

The type of the primary endocrine and/or neuroendocrine tumour solid cancer being assessed and/or treated.

The subcategory of the primary endocrine and/or neuroendocrine tumour solid cancer being assessed and/or treated.

The type of the primary endocrine solid cancer being assessed and/or treated.

The type of primary eye and/or orbit solid cancer being assessed and/or treated.

The body location used to describe the point of origin for conjunctiva cancer or an ‘Other’ value.

The body location used to describe the point of origin for eyelid cancer or an ‘Other’ value.

The body location used to describe the point of origin for lacrimal drainage system cancer or an ‘Other’ value.

The body location used to describe the point of origin for lacrimal gland cancer or an ‘Other’ value.

The body location used to describe the point of origin for lens of eye cancer or an ‘Other’ value.

The body location used to describe the point of origin for other eye and/or orbit cancer or an ‘Other’ value.

The body location used to describe the point of origin for retina cancer or an ‘Other’ value.

The body location used to describe the point of origin for sclera cancer or an ‘Other’ value.

The body location used to describe the point of origin for eye and/or orbit cancer or an ‘Other’ value.

The body location used to describe the point of origin for uveal tract cancer or an ‘Other’ value.

The body location used to describe the point of origin for cervix uteri cancer or an ‘Other’ value.

The body location used to describe the point of origin for corpus uteri cancer or an ‘Other’ value.

The body location used to describe the point of origin for fallopian tube cancer or an ‘Other’ value.

The body location used to describe the point of origin for gestational trophoblastic disease cancer or an ‘Other’ value.

The body location used to describe the point of origin for ovary cancer or an ‘Other’ value.

The body location used to describe the point of origin for peritoneum cancer or an ‘Other’ value.

The body location used to describe the point of origin for female genital cancer or an ‘Other’ value.

The body location used to describe the point of origin for uterine ligament cancer or an ‘Other’ value.

The body location used to describe the point of origin for vagina cancer or an ‘Other’ value.

The body location used to describe the point of origin for vulva cancer or an ‘Other’ value.

The grade of a follicular lymphoma, assessed using the follicular lymphoma grading system.

The body location used to describe the point of origin for anal cancer or an ‘Other’ value.

The body location used to describe the point of origin for appendiceal cancer or an ‘Other’ value.

The body location used to describe the point of origin for biliary cancer or an ‘Other’ value.

The type of the primary gastrointestinal solid cancer being assessed and/or treated.

Specimen collection endoscopic resection procedures used in the diagnosis of gastrointestinal colorectal cancer or an ‘Other’ value.

Lymph nodes used for diagnosis of gastrointestinal colorectal cancer or an ‘Other’ value.

Specimen collection metastecomy resection procedures used in the diagnosis of gastrointestinal colorectal cancer or an ‘Other’ value.

Specimen collection operative resection procedures used in the diagnosis of gastrointestinal colorectal cancer or an ‘Other’ value.

Specimen collection procedures used in the diagnosis of gastrointestinal colorectal cancer or an ‘Other’ value.

The body location used to describe the point of origin for colorectal cancer or an ‘Other’ value.

The body location used to describe the point of origin for cancer of the duodenum or an ‘Other’ value.

The body location used to describe the point of origin for cancer of the endocrine pancreas or an ‘Other’ value.

The body location used to describe the point of origin for cancer of the exocrine pancreas or an ‘Other’ value.

The body location used to describe the point of origin for cancer of the ileum and/or jejunum or an ‘Other’ value.

The body location used to describe the point of origin for cancer of the liver or an ‘Other’ value.

Lymph nodes used for diagnosis of gastrointestinal cancer or an ‘Other’ value.

The body location used to describe the point of origin for oesophageal cancer or an ‘Other’ value.

The body location used to describe the point of origin for pancreatic cancer or an ‘Other’ value.

The body location used to describe the point of origin for rectal cancer or an ‘Other’ value.

The body location used to describe the point of origin for cancer of small intestine or an ‘Other’ value.

The body location used to describe the point of origin for stomach cancer or an ‘Other’ value.

The subcategory of the primary gastrointestinal solid cancer being assessed and/or treated.

The body location used to describe the point of origin for gastrointestinal cancer or an ‘Other’ value.

The type of primary non prostate genitourinary solid cancer being assessed and/or treated.

The type of the primary genitourinary solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

The type of the primary genitourinary solid cancer being assessed and/or treated.

The subcategory of the primary genitourinary solid cancer being assessed and/or treated.

The type of the primary gynaecological solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

The type of the primary gynaecological solid cancer being assessed and/or treated.

Systems that may be used to score the prognostic factors of a haematological cancer diagnosis or an “other value”

Systems that may be used to classify the stage of a haematological cancer or an “other value”

The category of haematologic cancer being assessed and/or treated.

The subcategory of haematologic cancer being assessed and/or treated.

Intents or reasons for using a therapeutic procedure to treat haematological cancers.

The subcategory of the primary head and/or neck solid cancer being assessed and/or treated.

The type of the primary hepatopancreaticobiliary solid cancer being assessed and/or treated.

The high-level body location used to describe the point of origin for all cancer types or an ‘Other’ value.

A body structure where cancer may be present, which is a paired either side of the body’s midline or an ‘Other’ value.

The side of a paired organ (e.g. left or right).

The side of a paired organ (e.g. left or right) or a ‘Not applicable’ value.

The side of a paired organ (e.g. left or right) or an ‘Unknown’ value.

The side of a paired organ or midline structure, e.g. left, right, central.

The type of leukaemia haematologic cancer being assessed and/or treated.

The subcategory of leukaemia haematologic cancer being assessed and/or treated.

The body location used to describe the point of origin for lower gastrointestinal cancer or an ‘Other’ value.

Lymph nodes used for diagnosis of cancer or an ‘Other’ value.

The type of lymphoma haematologic cancer being assessed and/or treated.

The subcategory of lymphoma haematologic cancer being assessed and/or treated.

The type of the primary male genital solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

The body location used to describe the point of origin for other male genital cancer or an ‘Other’ value.

The body location used to describe the point of original for male genital cancer or an ‘Other’ value.

The type of mastocytosis haematologic cancer being assessed and/or treated.

The type of mature T-cell and/or natural killer cell neoplasm cancer being assessed and/or treated.

Intents or reasons for using a therapeutic procedure to treat solid tumours.

The type of the primary melanoma solid cancer being assessed and/or treated.

A body structure where cancer may be present, which is symmetrical on the body’s midline or an ‘Other’ value.

The neoadjuvant therapy response score for tumours, defined using the modified Ryan tumour regression score plus not administered value.

The type of myelodysplastic-myeloproliferative haematologic cancer being assessed and/or treated.

The type of myeloid proliferation and/or myeloid neoplasm haematologic cancer being assessed and/or treated.

The type of myeloproliferative haematologic cancer being assessed and/or treated.

The type of the primary nasal cavity and paranasal sinus solid cancer being assessed and treated.

The type of neoadjuvant therapy that has been performed or an ‘Unknown’ value.

A scoring system system used to measure a patient’s response to neoadjuvant therapy.

The type of the primary neuroendocrine tumour gastroenteropancreatic (GEP) solid cancer being assessed and/or treated.

The type of the primary neuroendocrine solid cancer being assessed and/or treated.

The type of the primary neuroendocrine tumour non-gastroenteropancreatic (non-GEP) solid cancer being assessed and/or treated.

The subcategory of the primary neuroendocrine solid cancer being assessed and/or treated.

The type of non Hodgkin lymphoma haematologic cancer being assessed and/or treated.

The reason why the procedure and/or test was not performed.

The grade of a breast cancer, assessed using the nuclear ductal carcinoma in situ grading system.

Observable entities used to represent the meaning of CanShare data elements.

The body location used to describe the point of origin for orbit cancer or an ‘Other’ value.

The type of the primary head and/or neck other than oral cavity or mobile tongue primary, major salivary gland primary, odontogenic primary, nasal cavity and paranasal sinus primary, ear primary, pharynx, larynx and trachea primary solid cancer being assessed and/or treated.

The performance status of the procedure and/or test.

The type of the primary pharynx and/or larynx and/or trachea solid cancer being assessed and/or treated.

The type of plasma cell haematologic cancer being assessed and/or treated.

Presence of tumour findings in relation to prognostic factors of a cancer diagnosis.

A body location used to describe the point of origin for a cancer type, or an ‘Other’ value.

An activity involved in the performance of healthcare

Systems that may be used to score the prognostic factors of a cancer diagnosis or an “other value”

The type of cancer recurrence, e.g. local, regional plus unknown and not applicable values.

The simple cancer pathway by which the patient was referred for the given service ie screening or diagnostic.

The revised stage groups for primary cutaneous T-cell lymphoma, defined using TNM-B category staging system.

The type of cancer service that is currently, or should in the future, treat this cancer.

The side of a body structure that is symmetrical to the midline, e.g. left side, right side, both sides, central, or a ‘definitely not present’ value.

The side of a body structure that is symmetrical to the midline, e.g. left side, right side, both sides, central, or a ‘unknown’ value.

The type of the primary skin and/or melanoma solid cancer being assessed and/or treated.

The subcategory of the primary skin and/or melanoma solid cancer being assessed and/or treated.

The type of the primary skin solid cancer being assessed and/or treated.

The body location used to describe the point of origin for skin cancer or an ‘Other’ value.

The type of the primary soft tissue and/or bone solid cancer being assessed and/or treated.

The subcategory of the primary soft tissue and/or bone solid cancer being assessed and/or treated.

The type of the primary soft tissue solid cancer being assessed and/or treated.

The type of the primary solid cancer being assessed and treated, by systemic anti-cancer therapy (SACT).

Grading systems used to assess the grade of a solid tumour.

Systems that may be used to classify the stage of a solid tumour or an “other value”

The category of the primary solid cancer being assessed and/or treated.

The subcategory of the primary solid cancer being assessed and/or treated.

The type of cancer spread eg. local invasion, distant metastasis plus unknown and not applicable values.

Systems that may be used to classify the stage of a cancer diagnosis or an “other value”

The category of the primary cancer being assessed and/or treated.

The subcategory of the primary cancer being assessed and/or treated.

The reason why the test failed.

The reason why the test result is inconclusive.

The type of the primary thoracic solid cancer being assessed and/or treated.

Lymph nodes used for diagnosis of thoracic lung cancer or an ‘Other’ value.

The body location used to describe the point of origin for lung cancer or an ‘Other’ value.

Lymph nodes used for diagnosis of thoracic cancer or an ‘Other’ value.

The body location used to describe the point of origin for pericardium cancer or an ‘Other’ value.

The body location used to describe the point of origin for pleura cancer or an ‘Other’ value.

The body location used to describe the point of origin for soft tissue sarcoma of thorax and/or mediastinum primary or an ‘Other’ value.

The body location used to describe the point of origin for thymus cancer or an ‘Other’ value.

The body location used to describe the point of origin for thorax cancer or an ‘Other’ value.

A body location used to describe the point of origin for a cancer type, a specimen, a procedure location, or an ‘Other’ value.

Treatment intents or reasons for using a therapeutic procedure to treat cancer.

The suspected origin of the tumour clinically assessed.

The type of primary cancer being assessed.

The unknown body location of a cancer.

The type of the primary upper gastrointestinal solid cancer being assessed and/or treated.

The body location used to describe the point of origin for upper gastrointestinal cancer or an ‘Other’ value.

The body location used to describe the point of origin for testicular cancer or an ‘Other’ value, in the context of systemic anti-cancer therapy (SACT).

The body location used to describe the point of origin for kidney cancer or an ‘Other’ value.

The body location used to describe the point of origin for penis cancer or an ‘Other’ value.

The body location used to describe the point of origin for prostate cancer or an ‘Other’ value.

The body location used to describe the point of origin for renal pelvis and ureter cancer or an ‘Other’ value.

The body location used to describe the point of origin for testicular adnexa cancer or an ‘Other’ value.

The body location used to describe the point of origin for testis cancer or an ‘Other’ value.

The body location used to describe the point of origin for urinary and male genital cancer or an ‘Other’ value.

The body location used to describe the point of origin for urethra cancer or an ‘Other’ value.

The body location used to describe the point of origin for urinary bladder cancer or an ‘Other’ value.

The body location used to describe the point of original for urinary system cancer or an ‘Other’ value.

NZ Ethnicity level 1 codes only.

Ethnicity level 2 codes

All level 4 NZ ethnic groups according to Stats NZ.

The type of histiocytic and/or dendritic cell haematologic cancer being assessed and/or treated.

Whether or not perforation of colon is or is not identified.

Reason for performing one or more operations on information, which may be permitted by source system’s security policy in accordance with one or more privacy policies and consent directives. Usage Notes: The rationale or purpose for an act relating to the management of personal health information, such as collecting personal health information for research or public health purposes.

Toxicity factors that may result in the discontinuation of a systemic anti-cancer therapy (SACT) treatment.

NZMT concept type

NZMT MP (SPS)

A LOINC FHIR ValueSet of NZPOCS Observation Code Set

ValueSet for Vaping Status based on the New Zealand vaping status reference set.

Histologies used for B-cell lymphoid neoplasm (WHO Classification of Tumours, Haematolymphoid Tumours) which are not Castleman disease, Acute lymphoblastic leukaemia , Indolent non-Hodgkin B cell lymphoma, Aggressive non-Hodgkin B cell lymphoma, Hodgkin lymphoma or Plasma cell disorders or an ‘Other’ value.

Histologies used for Castleman disease (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

Histologies used for other myeloid proliferations and neoplasms (WHO Classification of Tumours, Haematolymphoid Tumours) or an ‘Other’ value.

The 2 week referral criteria published by the Ministry of Health for outpatient colonoscopies.

The 6 week referral criteria published by the Ministry of Health for outpatient colonoscopies.

Body sites that are accessed by a surgeon during a colonoscopy procedure or an ‘Other’ value.

Primary Healthcare Organization

The reason for the current status of PractitionerRole

IPS Pregnancies Summary

IPS Expected Delivery Date Method

IPS Pregnancy Status

Problem Severity. The condition-severity value set from the base Condition resource is now the preferred binding for IPS. This value set of LOINC answer codes is retained as an additional binding for backward compatibility with the prior IPS release.

This value set indicates the level of medical judgment used to determine the existence of a problem.

This value set provides a category for the condition as a clinical problem for inclusion in the patient summary.

This value set includes codes from SNOMED Clinical Terms®: descendants of 404684003 |Clinical finding (finding) |, descendants of 243796009 |Situation with explicit context (situation)| and descendants of 272379006 |Event (event)|. The descendants of 71388002 |Procedure (procedure)| (which were included in the CORE problem list) are not included, as they are expected to be represented separately in the History of Procedures Section.

This value set includes codes from SNOMED Clinical Terms®: descendants of 404684003 |Clinical finding (finding) |, descendants of 243796009 |Situation with explicit context (situation)| and descendants of 272379006 |Event (event)| but excludes descendants of 71388002 |Procedure (procedure)|, as they are expected to be represented separately in the History of Procedures Section.

This value set includes codes from SNOMED Clinical Terms®: descendants of 71388002 |Procedure (procedure)|, excluding [all subtypes of 14734007 |Administrative procedure (procedure)|, all subtypes of 59524001 |Blood bank procedure (procedure)|, all subtypes of 389067005 |Community health procedure (procedure)|, all subtypes of 442006003 |Determination of information related to transfusion (procedure)|, all subtypes of 225288009 |Environmental care procedure (procedure)|, all subtypes of 308335008 |Patient encounter procedure (procedure)|, all subtypes of 710135002 |Promotion (procedure)|, all subtypes of 389084004 |Staff related procedure (procedure)|].

This value set includes codes from SNOMED Clinical Terms®: descendants of 71388002 |Procedure (procedure)|, excluding [all subtypes of 14734007 |Administrative procedure (procedure)|, all subtypes of 59524001 |Blood bank procedure (procedure)|, all subtypes of 389067005 |Community health procedure (procedure)|, all subtypes of 442006003 |Determination of information related to transfusion (procedure)|, all subtypes of 225288009 |Environmental care procedure (procedure)|, all subtypes of 308335008 |Patient encounter procedure (procedure)|, all subtypes of 710135002 |Promotion (procedure)|, all subtypes of 389084004 |Staff related procedure (procedure)|], plus IPS codes for absent/unknown procedures.

The code list represents the current practicing status of the Provider Person as per their registration with an RA.

Blood group [Type]

This value set is defined as the union of: (a) Blood group [Type]; (b) Presence/Absence Indicators (2.16.840.1.113883.11.22.52) (c) Microorganisms (2.16.840.1.113883.11.22.49)

This value set includes codes from SNOMED Clinical Terms (SNOMED CT®) that are included in: all descendants of 106253005 |Histologic grading differentiation AND/OR behavior (qualifier value)|, all descendants of 373369003 |Finding of histologic grading differentiation AND/OR behavior (finding)|, all descendants of 399981008 |Neoplasm and/or hamartoma (disorder)|.

Value Set Definition: LOINC {STATUS in {ACTIVE}, CLASSTYPE in {1}, CLASS exclude {CHALSKIN, H&P.HX.LAB, LABORDERS, NR STATS, PATH, PATH.*, MOLPATH, MOLPATH.*, CYTO, HL7.CYTOGEN, HL7.GENETICS}}

This is a value set of the SNOMED CT microorganism concepts for use in the Results section observation values.

Value Set Definition:

LOINC {STATUS in {ACTIVE}, CLASSTYPE in {1}, CLASS in {CYTO, HL7.CYTOGEN, HL7.GENETICS, MOLPATH, MOLPATH.*, PATH, PATH.*}}

Extensible value set including SNOMED CT and DICOM concepts for Linear, Area and Volume Measurements

Value Set Definition: LOINC {CLASS in {RAD}}

IPS Results Radiology Textual Observations

IPS Specimen Type value set. This value set includes a set of codes from SNOMED CT that may be used to represent specimen types.

Value set to support FHIR resource for identifying the rheumatic fever care plan being provided.

The value set to support rheumatic fever data collection.

This value set includes some taken and not taken reason codes from SNOMED CT - provided as an exemplar

A coded type for professional scope of practice.

FHIR ValueSet for UKPUL

This identifies the vaccine substance administered - CVX codes.

This value set includes the codes from SNOMED CT describing Vaccine Target Diseases.

This value set provides a list of types of vaccine, plus IPS codes for absent/unknown immunizations. It includes codes from SNOMED Clinical Terms®: all descendants of 787859002 |Vaccine product (product)|.

This value set indicates the allowed vital sign result types. The LOINC code for Vitals Signs panel (85353-1) is a grouping structure for a set of vital signs and includes related links (with type=has-member) to the Observations in this set (e.g. respiratory rate, heart rate, BP). The Blood pressure panel (85354-9) is used to group the component observations Systolic blood pressure (8480-6) and Diastolic blood pressure (8462-4).

Common UCUM units for recording Vital Signs

A FHIR CodeSystem of Australian and New Zealand Standard Classification of Occupations

Additional authorisations that a practitioner is authorised to practice or prescribe.

Admission source code for use when reporting into National Collections

Admission types to be used for reporting into National Collections

Agency type code to be used in reporting to National Collection

Preferred value set for AllergyIntolerance Clinical Status.

Terms for clinicians to identify when symptoms started to determine if a person is eligible for the COVID-19 antiviral

Canshare testing non-snomed concepts

Clinical code type code for use when reporting into National Collections

Clinical coding system code to be used for reporting to National Collections

New Zealand codes for Coverage category types

New Zealand codes for Coverage Types

DSM-IV

Possible datum codes

Te Whatu Ora list of domicile codes

EDQM - Standard Terms used in Switzerland (aggregations of codes of ValueSets RouteOfAdministration, Dose Form, see original codes system defined in https://standardterms.edqm.eu/#)

ISO 3166-1 establishes codes that represent the current names of countries, dependencies, and other areas of particular geopolitical interest, on the basis of country names obtained from the United Nations.

Description: Codes for the representation of names of languages — Part 2: Alpha-3 code, is the second part of the ISO 639 standard, which lists codes for the representation of the names of languages. The three-letter codes given for each language in this part of the standard are referred to as Alpha-3 codes. There are 487 entries in the list of ISO 639-2 codes. There are 21 languages that have alternative codes for bibliographic or terminology purposes, this code system only contains those with terminology purposes. Administered by SIL

Description: ISO 639-3 is a code that aims to define three-letter identifiers for all known human languages. At the core of ISO 639-3 are the individual languages already accounted for in ISO 639-2. The large number of living languages in the initial inventory of ISO 639-3 beyond those already included in ISO 639-2 was derived primarily from Ethnologue (15th edition). Additional extinct, ancient, historic, and constructed languages have been obtained from Linguist List. Administered by SIL

The feeding method of an infant at various stages post delivery

A FHIR CodeSystem of NZPOCS Observation Code Set - NZ Specific Code

Codes to record a person’s ethnicity, drawn from Level 4 of the Ethnicity code system described here

FHIR CodeSystem for MedDRA LLT 26.0

FHIR CodeSystem for MedDRA LLT 27.0

Medication Status Codes

Whether the application produces or consumes documents.

My New CS

Stats NZ’s Māori descent codes

NZ District Health Board (HPI-ORG) Codes

A FHIR CodeSystem of Iwi and iwi-related groups statistical classification

Additional codes to be incorporated with HL7 v3 Value Set Purpose of Use

A FHIR CodeSystem of Australian and Ethnicity New Zealand Standard Classification

Number of vessels identified in the umbilical cord

Omaha System CodeSystem including various domains.

Primary Healthcare Organization

The reason for the current status of PractitionerRole

This list to support rheumatic fever collection.

A classification of the type or range of health services that a practitioner is authorised to provide, as determined by the Responsible Authority or other statutory authority (e.g. PHARMAC), that is, what the practitioner can or cannot do. It includes Scope of Practice as defined by the Health Practitioners Competence Assurance Act 2003, any special authorisations granted, and any conditions or limitations imposed by the Responsible Authority.

Reason why initial skin to skin contact was ended

SNOMED CT identifiers assigned to Rheumatic Fever concepts that will not be available until April 2024 edition. Codesystem need to be retired once they have been uploaded in SNOMED NZ Edition

Used in Organization and Location to indicate what is the type of Alias

The Unified Code for Units of Measure (UCUM) is a code system intended to include all units of measures being contemporarily used in international science, engineering, and business. The purpose is to facilitate unambiguous electronic communication of quantities together with their units. The focus is on electronic communication, as opposed to communication between humans. A typical application of The Unified Code for Units of Measure are electronic data interchange (EDI) protocols, but there is nothing that prevents it from being used in other types of machine communication.

HISO 10050 Uterotonic drugs administered status, as part of the third stage of labour.

The CDC’s National Center of Immunization and Respiratory Diseases developed and maintains the CVX (vaccine administered) code set. It includes both active and inactive vaccines available in the US.

canshare-test-nonsnomed

A set of codes specifying the motivation, cause, or rationale of an Act, when such rationale is not reasonably represented as an ActRelationship of type “has reason” linking to another Act. Examples: Example reasons that might qualify for being coded in this field might be: “routine requirement”, “infectious disease reporting requirement”, “on patient request”, “required by law”.